Introduction
============

Benign prostatic hyperplasia (BPH) is a pathological symptom frequently found in the elderly population. Treatment options for men with symptomatic BPH include active monitoring, phytochemical treatment, medical therapy with α-blockers or 5-α-reductase inhibitors, and surgery ([@B2]; [@B31]). The use of complementary and alternative medicine (CAM) for the treatment of BPH patients has a long history, especially in European countries ([@B24]; [@B25]). Nevertheless, there is still a considerable degree of skepticism from the urologic community about the efficiency and safety of these CAM products. This is mainly due to the lack of an established mechanism of action for CAM ([@B21]; [@B36]) materials. The CAM used in this trial was pumpkin seed oil, saw palmetto oil and a combination of pumpkin seed oil and saw palmetto oil ([@B12]; [@B14]). For these materials, the mechanisms of action may include alteration of cholesterol metabolism, anti-androgenic activity (including 5-α-reductase inhibitor activity), anti-inflammatory effects, and a decrease in available sex hormone binding globulin ([@B9]). Although the mechanisms of action of these materials have been investigated in many *in vitro* and indirect *in vivo* studies, they have yet to be clearly defined ([@B27]; [@B34]). Nevertheless, many BPH patients are currently taking these CAM materials everyday without apparent adverse effects ([@B30]). Yet, long-term treatment of BPH patients with CAM is necessary in order to assess the occurrence of side effects. Therefore, the objective of this study was to carry out a long-term study to determine the effectiveness and the potential side effects of pumpkin seed oil and/or saw palmetto oil in the treatment of Korean men with symptomatic BPH.

Materials and Methods
=====================

Study design
------------

BPH patients with an international prostate symptom score (IPSS) of 8 or more participated in a randomized, double-blind, placebo-controlled trial of pumpkin seed oil and saw palmetto oil for a 12-month period. Volunteers were requested to sign the documents of clinical examinations agreement after careful review of the instructions. Clinical examinations were conducted for 18 months at Chung-Ang University Medical Center, Department of Urology.

By baseline checkup of general health, patients with any major diseases except BPH or patients who had BPH related treatment such as 5-α-reductase inhibitor, α-receptor blocker, urogenital surgery or any other alternative therapy for BPH were excluded. Any other medication or surgery related to BPH was not allowed during the trial.

Sixty-two patients were distributed into 4 separate groups according to their time sequence of participation; group A (placebo, control, sweet potato starch, 320 mg/day), group B (pumpkin seed oil, 320 mg/day), group C (saw palmetto oil, 320 mg/day) and group D (the combination of pumpkin seed oil, 320 mg/day and saw palmetto oil, 320 mg/day). Sweet potato starch (Bum-Ah, Seoul, Korea), standardized pumpkin seed oil and saw palmetto oil (RIA International, New Jersey, USA) were prepared in hard capsules. Patients took 2 capsules per day in the morning and the evening after a meal, over a 12-month period. After the baseline assessment of general health, each participant visited the hospital every 3 months to measure BPH parameters such as IPSS, quality of Life score (QoL), serum prostate specific antigen (PSA), prostate volume (PV) and maximal urinary flow rate (MFR). Fifteen patients (24%) were dropped during the trial due to aggravation of symptoms (n=13), movement (n=2) and initiation of BPH medication (n=1).

Finally, 47 patients were completely participated in our study. They have been checked on overall functioning, difficulties with intervention adherence and adverse symptoms weekly by phone, and visited hospital every 3 months.

Measurements
------------

IPSS and QoL were assessed using standard questionnaire forms (2003 American Urology Association Guideline on the Management of BPH: Diagnosis and Treatment Recommendations) ([@B37]). The questionnaire for IPSS is composed with seven questions and each measured on a 5 point scale. For the assessment, the patients responded on a scale of 0 (delighted) to 6 (terrible) to the question, \"If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about this?\" The serum PSA was measured using an electrochemiluminescence method ([@B8]) (Elecsys systems modular E-170, Roche diagnostics GmbH, Germany). PV was measured using transrectal ultrasonography ([@B8]) (Voluson 730 proV GE Healthcare, Austria), and MFR was done using an uroflowmeter ([@B33]) (Medtronic Urodyn 1000, High Med, Denmark). PV and MFR measurements started after 6 months because the urologists advised that there would not be a significant change over a short period such as the first 3 months of treatment. All patients were measured for body weight, height and body mass index (BMI) (Fanics Co. Ltd, HM-170, Korea) at the beginning of the experiment.

Statistical analysis
--------------------

The differences among groups and experimental periods of each group were analyzed by Tukey\'s studentized range test for BPH parameters. BPH parameters for IPSS, QoL, serum PSA, PV and MFR were expressed as the mean ± standard error, and were age adjusted against group A (control), in which acquired by analysis of covariance (ANCOVA) with least square mean (LSMEAN). Also Pearson correlation was compared between parameters. SAS 9.01 (SAS Institute Inc., Cary, NC, USA) was used for statistical analysis.

Results
=======

General characteristics for the patients are shown in [Table 1](#T1){ref-type="table"}. The average age of patients who completed the 1 year trial was 53.3 years, and the average age of group D was significantly higher than those of groups B and C ([Table 1](#T1){ref-type="table"}). The average height, weight and BMI of patients were not significantly different among groups, and the average BMIs of all groups were within an overweight range based on Korean obesity evaluation criteria ([@B18]).

IPSSs in groups B, C and D were significantly reduced (*P* \< 0.05) after 3 months of treatment ([Table 2](#T2){ref-type="table"}). IPSS of group B was decreased by 12.0 points (58.0% change), from 20.7 to 8.7 after 12-month treatment. IPSS of group C was also decreased by 9.2 points (50.3% change), from 18.2 to 9.1. The average IPSS of group D showed a constant decline from the beginning (19.0) to the end of the 12-month treatment (4.7) by 14.3 points, indicating 75.3% improvement in voiding symptoms. In particular, BPH status of group D was improved from moderate (8\~19) to mild (≤7) according to IPSS. The reduction of IPSS after 12 month treatment was highest in group D, however, there was no significant difference among the groups.

The QoL were significantly improved in groups B and C after 3 months, and in group D after 6 months (*P* \< 0.05) ([Table 3](#T3){ref-type="table"}). The QoL score of group A (placebo) was not changed, but those of group B and group C were reduced by 1.7 points (40.5% change) and 1.4 points (38.9% change) after 12-month treatment, respectively. The QoL score of group D was reduced by 2.2 points (57.9% change) after 12-month treatment.

Serum PSA levels are shown in [Table 4](#T4){ref-type="table"}. The serum PSA levels of groups A, B and C remained unchanged during the 12 month trial. The serum PSA levels of group D showed a constant decline from the beginning (1.2 ng/ml) to the end of the 12-month treatment (0.7 ng/ml), indicating 41.7% reduction.

The PV of groups B, C and D showed a gradual decline over the experimental period, but these changes were not statistically significant ([Table 5](#T5){ref-type="table"}). The PV of group A remained unchanged over the experimental period.

As shown in [Table 6](#T6){ref-type="table"}, the MFR of group A was gradually decreased over the experimental period with a worsening in urinary symptoms. The MFR of group B was significantly increased after 6 months and that of group C was significantly increased at 12 months (*P* \< 0.05). The MFR of group B was increased from 14.8 ml/second at the initiation of the study to 17.0 ml/second at the end, for an improvement of 14.9%. The MFR of group C was increased from 14.0 to 21.2 ml/second after 12-month treatment, which was an improvement of 51.4%. The MFR score of group D, however, was not changed significantly during the treatment period.

Correlation between parameters existed; IPSS vs QoL (Correlation coefficient = 0.635, *P* \< 0.05), IPSS vs MFR (Correlation coefficient = -0.375, *P* \< 0.05), QoL vs MFR (Correlation coefficient = -0.255, *P* \< 0.05), and prostate volume vs serum PSA (Correlation coefficient = 0.323, *P* \< 0.05).

In the meanwhile, there were no statistically significant differences in all BPH parameters among groups at every treatment time.

Discussion
==========

The use of phytochemicals (phytosterols) as an alternative therapy for the relief of lower urinary tract symptoms due to a prostatic disease seems to be growing quickly all over the world, including the Republic of Korea ([@B5]). A phytochemical based therapy is widely given to men with symptomatic BPH in Western Europe, where physicians prescribe phytochemical products in the same manner as they prescribe drugs ([@B19]).

The results of this study show that the symptoms of BPH for all patients receiving treatment with pumpkin seed oil, saw palmetto oil, or a combination of pumpkin seed oil plus saw palmetto oil were improved over 12 months, in comparison with placebo. But therapeutic efficiency was not improved by combination of these two compounds. During the experimental period, no side effects were reported; this was in contrast with Singh et al. ([@B28]) in similar trials.

According to Braeckman\'s study ([@B3]), oral doses of saw palmetto oil 160 mg twice daily for 3 months improved IPSS about 22% after 45 days and 35% at 90 days. This was comparable with our result in which group B (33.8%) and group C (33.2%) showed similar improvement after 3 months. In the study by Bach ([@B1]), 12-month pumpkin seed treatment improved the IPSS at least 5 points and overall improvement of 64.8%. In a double-blind randomized trial that compared the effects of saw palmetto (320 mg/day) with 5-α-reductase inhibitor (5 mg/day), the IPSS was declined by 37% and 39%, respectively ([@B7]) after 6 months of treatment. Hisashi et al. ([@B15]) reported a significant linear relationship between IPSS and QoL score, a finding in agreement with our own, in which IPSS was correlated exactly with QoL score. Both IPSS and QoL score tended to decline significantly at the 3rd month of treatment in our study, a finding similar to that of other researchers ([@B23]; [@B33]).

There have been recent reports suggesting that the serum PSA value may not be the best marker for prostate cancer detection, but it still remains one of the simplest means of early diagnosis and follow-ups for this disease. Serum PSA is also increased in other conditions such as BPH, prostatitis and others ([@B17]; [@B20]). Debruyne et al. ([@B10]) showed saw palmetto does not affect serum PSA level within 12 months of treatment. In our study, only a minimal change of PSA was observed within the normal range (0.0\~4.0 ng/ml), although a synergistic combination of pumpkin seed oil and saw palmetto oil may have contributed to the decrease of serum PSA level observed in our study.

Braeckman ([@B3]) showed that prostate volume was significantly decreased by 9% after 45 days and 10% after 90 days of treatment with saw palmetto oil. But several of reports demonstrated only a minimal change of prostate volume within 1 year ([@B19]; [@B35]). We also could not detect any significant decrease of the prostate volume even within 12 months.

In a randomized trial of natural products by Preuss et al. ([@B26]), the IPSS was decreased significantly after 90 days, but serum PSA, MFR and PV were not changed. This is in contrast to the present study in which the serum PSA of patients fed the combination of pumpkin seed oil and saw palmetto oil was decreased, and MFR in the pumpkin seed oil group was increased, significantly after 6 months.

In a study by Moon et al. ([@B22]), urinary flow rate of BPH patients supplemented with Sitosterol was increased from a baseline MFR of 9.3 ml/s to 12.2 ml/s after 4 weeks of treatment, and continued to increase consistently for 12 weeks. Kondas et al. ([@B16]) reported that the average MFR was increased from 10.36 ml/s to 14.44 ml/s without any adverse effects after 12 months of treatment with saw palmetto oil . In addition, this treatment did not influence the effectiveness of drugs taken for other chronic diseases by these patients. Carbin et al. ([@B6]) studied the combination of saw palmetto with pumpkin seed oil and reported a significant increase in MFR value in BPH patients after 3 months of treatment. Our study showed a similar effectiveness on MFR in the pumpkin seed oil group and the saw palmetto oil group, but the combination of pumpkin seed oil with saw palmetto oil group did not significantly affect MFR.

The action mechanism of pumpkin seed oil is well known by its inhibition on 5-α-reductase which converts testosterone into DHT (dihydrotestosterone) ([@B13]; [@B29]). Meanwhile various action mechanisms are suggested for saw palmetto oil, including nuclear estrogen receptor inhibitor ([@B11]), inhibition of cyclooxygenase and 5-lipoxygenase pathway ([@B4]) as well as 5-α-reductase inhibition ([@B32]). Recently, epithelial contraction in the prostate transition zone was demonstrated by Marks et al. ([@B19]). According to the difference in action mechanisms, a synergistic effect on BPH was expected from combination treatment of pumpkin seed oil and saw palmetto oil. In our study, combination treatment of pumpkin seed oil and saw palmetto oil induced a higher symptomatic improvement, though not statistically significant, in IPSS, QoL and PSA than a single treatment. A better result is expected by increasing subject numbers and longer observation period as well as *in vitro* mechanism studies.

Based on the results of this study, it could be suggested that pumpkin seed oil and saw palmetto oil are clinically safe and may be effective complementary and alternative medicine for BPH.
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Different superscripts within the same row are significantly different at α=0.05 by Tukey\'s studentized range test.
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Different superscripts within the same row are significantly different at α=0.05 by Tukey\'s range test with age adjusted.
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Different superscripts within the same row are significantly different at α=0.05 by Tukey\'s range test with age adjusted.
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Different superscripts within the same row are significantly different at α=0.05 by Tukey\'s range test with age adjusted.
